June 9, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of The Gap Inc. (“Gap” or “the Company”) (NYSE: GAP). Investors who purchased Gap securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Gap has violated… read more
June 8, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Medpace Holdings, Inc. (“Medpace” or “the Company”) (NASDAQ: MEDP). Investors who purchased Medpace securities prior to April 22, 2025, and continue to hold to the present, are encouraged to obtain additional… read more
June 8, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of New Era Energy & Digital, Inc. (f/k/a New Era Helium Inc.) (“New Era” or “the Company”) (NASDAQ: NUAI). Investors who purchased New Era securities prior to November 6, 2024, and continue… read more
June 8, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Gossamer Bio, Inc. (“Gossamer” or “the Company”) (NASDAQ: GOSS). Investors who purchased Gossamer securities prior to June 16, 2025, and continue to hold to the present, are encouraged to obtain additional… read more
June 8, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Aldeyra Therapeutics, Inc. (“Aldeyra” or “the Company”) (NASDAQ: ALDX). Investors who purchased Aldeyra securities prior to November 3, 2023, and continue to hold to the present, are encouraged to obtain additional… read more
June 8, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ADC Therapeutics SA (“ADC” or “the Company”) (NYSE: ADCT). Investors who purchased ADC securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether ADC has violated… read more
June 5, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biogen Inc. (“Biogen” or “the Company”) (NASDAQ: BIIB). Investors who purchased Biogen securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Biogen has violated federal… read more
June 4, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulcrum Therapeutics, Inc. (“Fulcrum” or “the Company”) (NASDAQ: FULC). Investors who purchased Fulcrum securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Fulcrum has violated… read more
June 4, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Abivax S.A. (“Abivax” or “the Company”) (NASDAQ: ABVX). Investors who purchased Abivax securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Abivax has violated federal… read more
June 4, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Medline Inc. (“Medline” or “the Company”) (NASDAQ: MDLN). Investors who purchased Medline securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Medline has violated federal… read more
June 3, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PrimeEnergy Resources Corporation (“PrimeEnergy” or “the Company”) (NASDAQ: PNRG). Investors who purchased PrimeEnergy securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether PrimeEnergy has violated… read more
June 1, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sivers Semiconductors AB (“Sivers” or “the Company”) (OTCMKTS: SIVEF). Investors who purchased Sivers securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Sivers has violated… read more
June 1, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Oculis Holding AG (“Oculis” or “the Company”) (NASDAQ: OCS). Investors who purchased Oculis securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Oculis has violated… read more
June 1, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating claims on behalf of investors in Caesars Entertainment, Inc. (“Caesars”) (NASDAQ: CZR). Investors who purchased Caesars and continue to hold to the present are encouraged to obtain additional information and assist the investigation. Caesars Investigation Details The investigation… read more
June 1, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Angi Inc. (“Angi” or “the Company”) (NASDAQ: ANGI). Investors who purchased Angi securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Angi has violated federal… read more
May 29, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of enGene Therapeutics Inc. (“enGene” or “the Company”) (NASDAQ: ENGN). Investors who purchased enGene securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether enGene has violated… read more
May 28, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BP p.l.c. (“BP” or “the Company”) (NYSE: BP). Investors who purchased BP securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether BP has violated federal… read more
May 27, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Zscaler, Inc. (“Zscaler” or “the Company”) (NASDAQ: ZS). Investors who purchased Zscaler securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Zscaler has violated federal… read more
May 27, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Grace Therapeutics, Inc. (“Grace” or “the Company”) (NASDAQ: GRCE). Investors who purchased Grace securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Grace has violated… read more
May 27, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Ducommun Incorporated (“Ducommun” or “the Company”) (NYSE: DCO). Investors who purchased Ducommun securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Ducommun has violated federal… read more
May 26, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Vital Farms, Inc. (“Vital Farms” or “the Company”) (NASDAQ: VITL). Investors who purchased Vital Farms securities prior to May 8, 2025, and continue to hold to the present, are encouraged to… read more
May 26, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ImmunityBio, Inc. (“ImmunityBio” or “the Company”) (NASDAQ: IBRX). Investors who purchased ImmunityBio securities prior to January 19, 2026, and continue to hold to the present, are encouraged to obtain additional information… read more
May 26, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Super Micro Computer, Inc. (“Super Micro” or “the Company”) (NASDAQ: SMCI). Investors who purchased Super Micro securities prior to February 2, 2024, and continue to hold to the present, are encouraged… read more
May 26, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Atara Biotherapeutics, Inc. (“Atara” or “the Company”) (NASDAQ: ATRA). Investors who purchased Atara securities prior to May 20, 2024, and continue to hold to the present, are encouraged to obtain additional… read more
May 26, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Rumble Inc. (“Rumble” or “the Company”) (NASDAQ: RUM). Investors who purchased Rumble securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Rumble has violated federal… read more
May 26, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of UP Fintech Holding Limited (“UP Fintech” or “the Company”) (NASDAQ: TIGR). Investors who purchased UP Fintech securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether… read more
May 26, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sleep Number Corporation (“Sleep Number” or “the Company”) (NASDAQ: SNBR). Investors who purchased Sleep Number securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Sleep… read more
May 21, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Doximity, Inc. (“Doximity” or “the Company”) (NYSE: DOCS). Investors who purchased Doximity securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Doximity has violated federal… read more
May 21, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sigma Lithium Corporation (“Sigma” or “the Company”) (NASDAQ: SGML). Investors who purchased Sigma securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Sigma has violated… read more
May 20, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Power Solutions International, Inc. (“Power Solutions” or “the Company”) (NASDAQ: PSIX). Investors who purchased Power Solutions securities prior to May 8, 2025, and continue to hold to the present, are encouraged… read more